- Company
- "Expanded access to Pergoveris…for older infertile women"
- by Son, Hyung Min Nov 14, 2025 06:12am
- The paradigm of infertility treatment is shifting amid the increased age of mothers and the expansion of the patient population with poor ovarian response (POR). Notably, the utilization of FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone) combination therapy has surged since the reimbursement criteria for 'Pergoveris inj (folli
- Policy
- Pricing nego for Erleada underway…last hurdle to reimb
- by Jung, Heung-Jun Nov 14, 2025 06:12am
- Janssen Korea's prostate cancer treatment Erleada (apalutamide) has entered price negotiations, the final hurdle for its reimbursement expansion in Korea. Erleada passed the Drug Reimbursement Evaluation Committee review last October and was deemed appropriate to expand reimbursement coverage to ‘high-risk non-metastatic castration-resis
- Company
- Generic company challenges flu drug Xofluza’s patent
- by Kim, Jin-Gu Nov 14, 2025 06:12am
- Roche's influenza treatment Xofluza (baloxavir marboxil) has become a generic company’s target for patent challenge. This marks the first patent challenge against Xofluza. Industry observers predict related patent challenges will continue in the near future. According to industry sources on the 13th, Kwangdong Pharmaceutical recently fil
- Company
- AZ runs Lung Health Check Bus…screens Changwon residents
- by Son, Hyung Min Nov 14, 2025 06:11am
- AstraZeneca Korea announced on the 12th that it operated a ‘Lung Health Check Bus’ equipped with AI-based chest X-ray technology at the ‘2025 Anti-Aging BIOHealth Expo (ABEXPO 2025)’, which was held at the Changwon Exhibition and Convention Center (CECO) in Gyeongsangnam-do from the 6th to the 8th, in collaboration with the Korea Tubercul
- Policy
- Ultomiris gains reimbursement approval for 'NMOSD·gMG'
- by Jung, Heung-Jun Nov 14, 2025 06:11am
- AstraZeneca's Ultomiris (ravulizumab) will receive reimbursement coverage for Neuromyelitis Optica Spectrum Disorder (NMOSD) this month, and its reimbursement scope will expand to generalized myasthenia gravis. Notably, the Ministry of Health and Welfare (MOHW) has requested reimbursement coverage for myasthenia gravis. Therefore, it was
- Policy
- Pharmaceutical post-market management system to be enhanced
- by Jung, Heung-Jun Nov 14, 2025 06:11am
- The National Health Insurance Service (NHIS) plans to revise its drug price negotiation and post-market management systems next year, with a focus on stable pharmaceutical supply. The NHIS will actively enforce penalties stipulated in its regulations if pharmaceutical companies discontinue drug supply without notification in violation of agre
- Policy
- MOHW and MOJ oppose legislating mandatory INN prescribing
- by Lee, Jeong-Hwan Nov 13, 2025 06:08am
- The Ministry of Health and Welfare and the Ministry of Justice have expressed reluctance toward a bill that would only partially mandate and enforce physician international non-proprietary name (INN) prescribing for government-designated drugs with unstable supply. Despite this being President Jae-Myung Lee’s presidential election pledge
- Company
- "Life-cycle prevention system completed with Prevenar 20"
- by Son, Hyung Min Nov 13, 2025 06:07am
- "As pneumococcal infections occur in both adults and children, the need to establish a full-life-cycle prevention is growing. Especially given the high mortality rates in children, the elderly, and chronic disease patients, prevention-centered management is considered important. With the recent launch of 'Prevenar 20,' the 20-valent pneumococcal
- Company
- Former AZ Director Do to lead New Business at Lilly Korea
- by Eo, Yun-Ho Nov 13, 2025 06:07am
- Former AstraZeneca Commercial Director David H. Do (39) has taken on a new leadership role at Lilly Korea. According to industry sources, Lilly Korea recently appointed AZ Commercial Director Do to lead its newly launched Neurology Business Division. . As a result, Director Do will oversee sales and marketing for Lilly's neurology produ
- Company
- UCB Korea appoints Edward Lee as new GM
- by Son, Hyung Min Nov 13, 2025 06:07am
- UCB Korea announced that Edward Lee has been appointed as its new General Manager, effective November 1. Edward Lee is an expert with over 15 years of experience in the global pharmaceutical industry, in areas ranging from Market Access, Medical Affairs, to Health Economics & Outcomes Research (HEOR). Lee has a strong background in drivin
